DECN Subsidiaries Plan Rebuttal Brief for Aug. 28th to Debunk J&J/Lifescan's Flawed Legal Reasoning and Factual Misrepresentations in Patent Case

Decision Diagnostics Corp.

Healthcare & Pharmaceutical

Share Tweet

DECN Subsidiaries Plan Rebuttal Brief for Aug. 28th to Debunk J&J/Lifescan's Flawed Legal Reasoning and Factual Misrepresentations in Patent Case

Company is Also Honored by Being Accepted into the Amazon Brand Registry, and Has Implemented its Plans to End Freeloading by Amazon Casual Sellers

LOS ANGELES, CA / ACCESSWIRE / August 24, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN), a manufacturer, quality plan administrator, and exclusive worldwide sales, service, and regulatory process agent for GenUltimate!™ glucose test strips, the pre-market ready GenSure!™, to be launched in International markets on September 5, 2017, and GenChoice!™ test strips, and the revolutionary meter and test strip system GenPrecis! The company's GenUltimate!™ glucose test strips work with the market leading Johnson & Johnson's ("J&J'') LifeScan OneTouch Ultra family of glucose testing meters. Today the company addresses two issues important to shareholders and the financial community regarding the company's litigation with the divisions of Johnson & Johnson, as well as the company's progress in retail markets through its inclusion in the Amazon Brand Registry.

In its comprehensive opposition brief to be filed on Aug. 28th, the company's subsidiaries Decision IT Corp. and PharmaTech Solutions Inc. plan to debunk J&J/Lifescan's flawed legal reasoning and factual misrepresentations that J&J/Lifescan are using to drag out the inevitable. If successful this would mark the second time J&J/Lifescan has been stymied by the court system in the current patent infringement case as they have again attempted to manipulate the system. The companies have battled J&J Lifescan through three previous litigations as defendants and are prosecuting the current case.

Keith Berman, CEO of Decision Diagnostics, commented, ''Our entire focus in this current patent infringement case against J&J/Lifescan is to create an environment where we can show the court how faulty J&J's legal reasoning is and to highlight many of the twisted stories and untruths they have lowered themselves to plead, in the current case and in the three previous cases.'' J&J/Lifescan have chosen to re-litigate the three earlier cases.

Mr. Berman continued, ''Once we file our opposition papers with the Nevada District Court on August 28, J&J/Lifescan will have approximately three (3) weeks to provide the trial judge with their final responses. We are feeling pretty good about our chances of prevailing. We expect the trial judge to take about six (6) weeks to rule on these matters, and once the trial judge rules we foresee the current case being positioned for a swift conclusion.''

In separate news, the company also reported that our ''Gen'' brand of products has been accepted into the Amazon Brand Registry, a major accomplishment. Up until our acceptance, our GenUltimate! product has been plagued in the Amazon Marketplaces by freeloading endeavors used by ''ghost'' on-line sellers, people and entities who advertise themselves as low price sellers, effectively lowering retail prices and stealing business from authorized sellers, oftentimes collecting money from diabetic users long before the GenUltimate! product is sourced for shipping. Inclusion in the Amazon Brand Registry effectively ends this practice, raising retail prices to a level where stability returns to this explosively growing market. The Brand Registry is already working.

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of August 23, 2017, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.


Decision Diagnostics Corp.
Keith Berman (805) 446-2973
[email protected]

SOURCE: Decision Diagnostics Corp.